optimum All News Consumer Pharma New Drugs Pipeline Clinical Trials FDA Alerts More New Breast Cancer Drug Ribociclib (Kisqali) May Benefit Younger Women, Too Print this page WEDNESDAY, Dec. 6, 2017 -- Adding a new drug to standard treatment can slow the progression of advanced breast cancer in younger women, a new clinical trial has found. The drug, called ribociclib ( Kisqali ), was approved by the U.S. Food and Drug Administration in March for the treatment of postmenopausal women with advanced breast cancer. Now, experts say, the drug is just as effective for premenopausal women. In the trial, the treatment typically doubled the time a woman remained free of cancer progression -- from roughly one year to two years. That benefit is "strikingly similar" to what's been seen in postmenopausal women, said Dr. Neil Iyengar, who specializes in treating breast cancer at Memorial Sloan Kettering Cancer Center in New York City. Breast cancer occurs most often in older women, and tumors that develop before menopause tend to be more aggressive, explained Iyengar. "This is an important study because it addresses the question of whether a treatment is as effective for premenopausal women as it is for postmenopausal women," he said. Iyengar was not involved in the research. Kisqali is one of several new drugs called CDK4/6 inhibitors. They work by blocking two proteins that help cancer cells grow and divide. The drug was specifically approved as a first-line treatment for postmenopausal women with advanced breast cancer that is hormone receptor-positive -- which means estrogen fuels the cancer's growth. It is meant to be used along with an aromatase inhibitor, a drug that blocks estrogen production in postmenopausal women. Aromatase inhibitors can be given to premenopausal women if they're used with medication that shuts down the ovaries' production of estrogen. The new trial involved 672 women with advanced breast cancer, aged 25 to 58, who were premenopausal or going through menopause. All of the women were given standard hormonal therapy -- an aromatase inhibitor or the drug tamoxifen -- plus ovary-suppressing medication. Half were randomly assigned to take Kisqali in addition. The other half took inactive placebo tablets. The main focus of the trial was "progression-free survival" -- how long a patient lives without the cancer getting worse. Overall, women taking Kisqali were typically progression-free for two years, versus 13 months for women on standard treatment only. The findings offer "clear proof" that the drug can work just as well for younger women, said the trial's lead researcher, Dr. Debu Tripathy. He's a professor of medicine and chairman of the breast medical oncology department at the University of Texas M.D. Anderson Cancer Center, in Houston. Tripathy cautioned, though, that Kisqali is not yet approved for premenopausal women. Last month, Kisqali's maker Novartis said it would "begin discussions" with drug regulators based on these trial results. Tripathy, who is a paid consultant to Novartis, was scheduled to present the findings Wednesday at the San Antonio Breast Cancer Symposium. Research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal. Kisqali does have downsides. For instance, it's known to often cause a drop in certain white blood cells that help fight off infections. In this study, three-quarters of the women who took Kisqali had a decline in blood cells called neutrophils, though most didn't have symptoms, according to Tripathy. A small number of women had what's called a QT prolongation -- a change in the heart's electrical activity that can trigger an abnormal heart rhythm. Novartis says that as a "precaution," Kisqali patients should have their heart activity checked before and during treatment. The study does not answer the question of whether the drug ultimately extends women's lives, Tripathy said. But, he added, that's a tough question, because once a woman's cancer progresses, she'll typically try other treatments -- like chemotherapy or newer "targeted" drugs. Iyengar agreed. And, he said, researchers are still trying to figure out the best course of treatment once patients do have a progression. For now, Iyengar said, "this study gives us new and convincing evidence that a lot of doctors and patients will want to consider." Cost, and what insurance will cover, is another issue. Kisqali, like other CDK4/6 inhibitors, costs thousands of dollars for one 28-day cycle of treatment. More information The U.S. Centers for Disease Control and Prevention has more on breast cancer in younger women . 2017 HealthDay. All rights reserved. Posted: December 2017 Recommended for you Print this page More News Resources FDA Medwatch Drug Alerts Daily MedNews Pharma Industry News New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Monthly Update Archive Latest Drug Information Updates Ozempic Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the treatment... Juluca Juluca (dolutegravir and rilpivirine) is a single-tablet, two-drug regimen of the approved drugs dolutegravir... Hemlibra Hemlibra (emicizumab-kxwh) is a bispecific factor IXa- and factor X-directed antibody indicated to prevent... Prevymis Prevymis (letermovir) a CMV DNA terminase complex inhibitor indicated for prophylaxis of cytomegalovirus... Fasenra Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated... Calquence Calquence (acalabrutinib) is a highly selective, potent, Bruton tyrosine kinase (BTK) inhibitor for the... More drug information updates FDA Consumer Updates Depression: FDA-Approved Medications May Help Dealing with ADHD: What You Need to Know Making Decisions for Your Health: Getting the Info You Need FDA: Cutting-Edge Technology Sheds Light on Antibiotic Resistance More FDA updates Latest FDA Drug Alerts Pharmacist Choice Alcohol Prep Pads by Simple Diagnostics: Recall - Lack of Sterility Assurance and Other Quality Issues December 5, 2017 Simple Diagnostics is voluntarily recalling three lots of Pharmacist Choice Alcohol Prep Pads (UPC # 898302001050, NDC # 98302-0001-05), which were... Albumin Human 25 Percent Solution (AlbuRx 25): Product Information Advisory - Fading Print On Label December 1, 2017 During routine inspection of retained AlbuRx 25% samples CSL Behring noted the potential for fading print with more effect on the expiration dating... Bull Capsules, Chao Jimengnan Tablets by Nutra Labs: Recall - Undeclared Drug Ingredients December 1, 2017 Nutra Labs Inc. is voluntarily recalling lots sold by their firm of the male enhancement supplements Bull 1800 mg Capsules with the production date... Subscribe via RSS Get alerts delivered by email More FDA Alerts Available RSS Feeds Select any link below to view the RSS feed. Daily MedNews Pharma Industry News FDA MedWatch Drug Alerts New Drug Approvals New Drug Applications Clinical Trials News Drugs in the Pipeline avatrombopag lofexidine patisiran patisiran volanesorsen revefenacin dasotraline Azedra IDP-118 Olinvo More booth
yule New Breast Cancer Drug Ribociclib (Kisqali) May Benefit Younger Women, Too worried
EmoticonEmoticon